[3H]N/OFQ [8008]
[3H]N/OFQ
| SMILES | CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O |
| InChIKey | PULGYDLMFSFVBL-SMFNREODSA-N |
| Sequence | FGGFTGARKSARKLANQ |
| HELM | PEPTIDE1{F.G.G.F.T.G.A.R.K.S.A.R.K.L.A.N.Q}$$$$ |
Chemical Properties
| Hydrogen bond acceptors | 26 |
| Hydrogen bond donors | 28 |
| Rotatable bonds | 62 |
| Log P | -11.480 |
| Molecular weight (Da) | 1808.0 |
| Stereochemistry info | partial |
| Radioactive | 3H |
No bioactivity data available.
[3H]N/OFQ
Drug properties
| Molecular type | Peptide |
| Physiological/Surrogate | Surrogate |
| Approved drug | No |
Distribution across phases (no. indications)
Phase I
0
Phase II
0
Phase III
0
Phase IV
0